The price of Aldeyra Therapeutics Inc. (NASDAQ: ALDX) closed at $6.53 in the last session, down -6.18% from day before closing price of $6.96. In other words, the price has decreased by -$0.43 from its previous closing price. On the day, 905622 shares were traded. ALDX stock price reached its highest trading level at $6.96 during the session, while it also had its lowest trading level at $6.45.
We take a closer look at ALDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.00 and its Current Ratio is at 10.00. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALDX now has a Market Capitalization of 382.63M and an Enterprise Value of 247.11M.
Stock Price History:
Over the past 52 weeks, ALDX has reached a high of $11.97, while it has fallen to a 52-week low of $4.95. The 50-Day Moving Average of the stock is 7.62, while the 200-Day Moving Average is calculated to be 7.99.
According to the various share statistics, ALDX traded on average about 1.07M shares per day over the past 3-months and 500.38k shares per day over the past 10 days. A total of 58.79M shares are outstanding, with a floating share count of 46.06M. Insiders hold about 2.80% of the company’s shares, while institutions hold 64.90% stake in the company. Shares short for ALDX as of Aug 30, 2023 were 6.09M with a Short Ratio of 6.09M, compared to 6.8M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 10.39% and a Short% of Float of 13.21%.
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.72, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.18 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$0.76 and -$1.88 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.09, with 7 analysts recommending between -$0.59 and -$1.85.
Based on 7 analysts’ estimates, the company’s revenue will be $44.69M in the next fiscal year. The high estimate is $76.28M and the low estimate is $5.71M. The average revenue growth estimate for next year is up 7,740.40% from the average revenue estimate for this year.